This extremely interesting study provides an important development for prostate cancer screening, and potentially even reveals a new target for the development of new prostate cancer drugs in the future
- Professor Malcolm Mason
The study, published in Oncogene this week, found much higher levels of the protein, NAALADL2, in prostate cancer tissue compared with healthy tissue. The difference was especially marked in aggressive prostate cancer tumours and cancer cells that had already spread around the body.
The team confirmed in two independent patient groups that the protein could be used to diagnose prostate cancer. But, even more importantly, it found that high levels of the protein could potentially pinpoint those patients with aggressive disease who would need surgery, chemotherapy and radiotherapy. Patients with lower levels of the protein were more likely to need monitoring rather than treatment.
After years of trying to unlock the secret of which prostate cancers are life-threatening – sometimes referred to as ‘tigers’, and which are essentially harmless ‘pussycats’, this new discovery could revolutionise how doctors treat the disease.
The protein NAALADL2 causes prostate cancer cells to behave more aggressively, making them more likely to move and invade healthy tissue surrounding the tumour.
Lead author, Dr Hayley Whitaker, Cancer Research UK scientist at the University of Cambridge, said: “This is early research, but if clinical trials confirm our results then it could help clinicians to tell which patients have a more aggressive tumour and need proportionally aggressive treatment, while sparing patients with low grade tumours a unnecessary radiotherapy or surgery.
“This is an important step along the path to developing a much-sought after test that could distinguish between different types of prostate cancer.”
Read the full story
Image: Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer)
Credit: Nephron
Reproduced courtesy of the University of Cambridge
______________________________________________________